IP Library Granted Patent US 12,618,113
Granted Patent B2
US 12,618,113 · App. 18/401,941 · Granted May 5, 2026

Genetic test kit for detecting thalassemia

Inventors: J. Francis Borgio (Dammam, SA); Sayed Abdulazeez (Dammam, SA); Fahd A. Al-Muhanna (Dammam, SA); Amein Kadhem Al-Ali (Dammam, SA)
Assignee: Imam Abdulrahman Bin Faisal University
C12Q1/6883C12Q1/6806C12Q1/686C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,618,113
App. No.
18/401,941
Granted
May 5, 2026
Kind
B2
Abstract

One aspect of the invention is a method for amplifying alpha globin genes HBA1, HBA2 and HBA12 in a single PCR tube to determine an HBA genotype of a subject. This method employs five primers selected to accurate and sensitively identify the HBA1, HBA2, and HBA12, a gene found at a higher frequency in citizens of Saudi Arabia, by accurately annealing to nucleic acids in a biological sample and simultaneously amplifying sequences encoding the alpha globin genes. This invention includes a procedure and required reagents for the amplification of alpha globin genes in a single PCR tube.

Claims (18)

1 . A genetic test kit, comprising:

a primer pool composition comprising a set of primers for each of HBA1, HBA2 and HBA12,

wherein the set of HBA1 primers comprises MA1F (SEQ ID NO: 3) and MA12R (SEQ ID NO: 4),

wherein the set of HBA2 primers comprises MA2F (SEQ ID NO: 5) and MA2R (SEQ ID NO: 2 or 6) and

wherein the set of HBA12 primers comprises MA12F (SEQ ID NO: 1) and MA2R (SEQ ID NO: 2 or 6);

wherein at least one of said HBA1, HBA2 or HBA12 primers in the primer pool composition has been modified by conjugation to a fluorescent tag, biotin, quencher or other detectable reporter moiety and/or by substitution of a chemically modified, non-natural nucleotide for at least one natural nucleotide; and

a polymerase chain reaction (PCR) tube, wherein the primer pool composition is present in the PCR tube.

2 . The genetic test kit of claim 1 , wherein the primer pool composition further comprises a human nucleic acid sample.

3 . The genetic test kit of claim 1 , wherein the primer pool composition further comprises a human nucleic acid sample, a DNA polymerase, dNTPs, a buffer solution, and bivalent cations and/or monovalent cations.

4 . The genetic test kit of claim 1 , wherein the primer pool composition comprises the set of HBA2 primers comprising MA2F (SEQ ID NO: 5) and MA2R (SEQ ID NO: 2).

5 . The genetic test kit of claim 1 , wherein the primer pool composition comprises the set of HBA2 primers comprising MA2F (SEQ ID NO: 5) and MA2R (SEQ ID NO: 6).

6 . The genetic test kit of claim 1 , wherein the primer pool composition comprises the set of HBA12 primers comprising MA12F (SEQ ID NO: 1) and MA2R (SEQ ID NO: 2).

7 . The genetic test kit of claim 1 , wherein the primer pool composition comprises the set of HBA12 primers comprising MA12F (SEQ ID NO: 1) and MA2R (SEQ ID NO: 6).

8 . The genetic test kit of claim 1 , wherein at least one of said HBA1, HBA2 or HBA12 primers in the primer pool composition has been modified by conjugation to a fluorescent tag.

9 . The genetic test kit of claim 1 , wherein at least one of said HBA1 , HBA2 or HBA12 primers in the primer pool composition has been modified by conjugation to biotin.

10 . The genetic test kit of claim 1 , wherein at least one of said HBA1, HBA2 or HBA12 primers in the primer pool composition has been modified by conjugation to a quencher.

11 . The genetic test kit of claim 1 , wherein at least one of said HBA1, HBA2 or HBA12 primers in the primer pool composition has been modified by substitution of a chemically modified, non-natural nucleotide for at least one natural nucleotide.

12 . The genetic test kit of claim 1 , wherein at least one of said HBA1, HBA2 and HBA12 primers in the primer pool composition has been modified by conjugation to a fluorescent tag, biotin, quencher or other detectable reporter moiety and/or by substitution of a chemically modified, non-natural nucleotide for at least one natural nucleotide.

Continuity (3)
Continuation 17332225 · May 27, 2021
Division 16257195 · Jan 25, 2019
Related Publication 20240132962A1 · Apr 25, 2024
References Cited (19)
US 20030050470A1 · An · 2003 [cited by applicant]
US 20050239069A1 · Maurer et al. · 2005 [cited by applicant]
US 20170268048A1 · Yang · 2017 [cited by applicant]
CN 1626671A · 2005 [cited by applicant]
CN 103421903B · 2015 [cited by applicant]
CN 105861661A · 2016 [cited by applicant]
CN 104894279B · 2016 [cited by applicant]
CN 106399478A · 2017 [cited by applicant]
CN 106636344A · 2017 [cited by applicant]
Traeger-Synodinos, et al. ; EMQN Best Practice Guidelines for molecular and haematology methods for carrier identification and prenatal diagnosis of the haemoglobinopathies ; European Journal of Human Genetics 23 ; pp. … [cited by applicant]
Mo ZP , et al. ; Detection of aglobin gene deletion and duplication using quantitative multiplex PCR of short fluorescent fragments. ; Clin Chem Lab Med 50 (4) ; pp. 649-654 ; Dec. 17, 2011 ; Abstract Only ; 1 Page. [cited by applicant]
Pornprasert, et al. ; Detection of α-thalassemia-1 Southeast Asian and Thai Type Deletions and β-thalassemia 3.5-kb Deletion by Single-tube Multiplex Real-time PCR with SYBR Green1 and High-resolution Melting Analysis ;… [cited by applicant]
Koren, et al. ; Response to hydroxyurea therapy in b-thalassemia ; American Journal of Hematology ; pp. 366-370 ; 2008 ; 5 Pages. [cited by applicant]
Borgio, et al. ; A novel HBA2 gene conversion in cis or trans: “α12 allele” in a Saudi population ; Blood Cells, Molecules and Diseases 53 ; pp. 199-203 ; Jul. 25, 2014 ; 6 Pages. [cited by applicant]
Borgio ; Molecular nature of alpha-gobin genes in the Saudi population ; Saudi Med J vol. 36 (11) ; 2015 ; 6 Pages. [cited by applicant]
Uchida, Gene Expression Profiling for Biomarker Discovery. In: Appasani, K. Southern E.M. (eds) Bioarrays, Humana Press, 2007. (Year: 2007). [cited by applicant]
Gen Bank Accession No. KY 472788.1, [cited by applicant]
Waye, Diagnostic testing for alpha-globin gene disorders in a heterogeneous North American population, Intl Jnl Lab Hem, 35, 306-313, 2013. (Year: 2013). [cited by applicant]
Gen Bank Accession No. NG_059271.1, [cited by applicant]